For example, small-molecule inhibition of EZH2 in glioblastoma and DIPG reduced tumourigenesis in vivo (Lan et al., 2017; Mohammad et al., 2017; Wang et al., 2017), whereas loss of EZH2 in medulloblastoma attenuated growth and promoted differentiation in vitro (Alimova et al., 2012). This evidence concerns the gene EZH2 and glioblastoma.